Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDC-0980 + bevacizumab + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a **four-drug combination regimen** consisting of GDC-0980 (a selective PI3K/mTOR inhibitor), bevacizumab (a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A), paclitaxel (a taxane-class microtubule inhibitor), and carboplatin (a platinum-based chemotherapeutic agent). GDC-0980 acts by inhibiting both PI3K and mTOR pathways, potentially overcoming resistance mechanisms in cancer cells. Bevacizumab blocks angiogenesis by neutralizing VEGF-A, impeding tumor vascularization. Paclitaxel disrupts mitosis by stabilizing microtubules, thereby preventing cell division, while carboplatin generates DNA cross-links, promoting apoptosis. This combination is under investigation for the treatment of solid tumors, particularly ovarian and lung cancers, aiming to synergize cytotoxic, anti-angiogenic, and pathway-targeted effects.
- Other names
- GDC-0980 + bevacizumab + paclitaxel + carboplatin
02
Targets
VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)mTOR (Mammalian target of rapamycin kinase)PIK3CA (Phosphoinositide 3-kinase alpha)DNAPIK3CB (Phosphatidylinositol 3-kinase beta subunit)
Beyond the preview
Go deeper on GDC-0980 + bevacizumab + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GDC-0980 + bevacizumab + paclitaxel + carboplatin.